Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Familial Amyotrophic Lateral Sclerosis Clear all
Completed No phase listed Observational Accepts healthy volunteers

Genetics of Familial and Sporadic ALS

NCT00821132
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease, Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS), Sporadic ALS (SALS)
Interventions
Genetic study of ALS families
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
13,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Not applicable Interventional

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

SOD1 Kinetics Measurements in ALS Patients

NCT03449212
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Familial, Amyotrophic Lateral Sclerosis, Sporadic
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

NCT02686268
View directory record Official record
Conditions
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Baltimore, Maryland • Amherst, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2Phase 3 Interventional

Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

NCT00706147
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Arimoclomol, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

NCT02414230
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biofluid Research on Age-Related or Inherited Neurodegeneration

NCT07798700
View directory record Official record
Conditions
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Not listed No phase listed Observational

Rehabilitation in SOD1 ALS Treated With Tofersen

NCT05725759
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Motor Neuron Disease, Familial
Interventions
Rehabilitation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ALS Research Collaborative

NCT06885918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
ALS Therapy Development Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

NCT01083667
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Pyrimethamine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

UPenn Observational Research Repository on Neurodegenerative Disease

NCT04715399
View directory record Official record
Conditions
Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Amyotrophic Lateral Sclerosis(ALS), Lewy Body Disease(LBD), Progressive Supranuclear Palsy(PSP), Corticobasal Syndrome(CBS), Posterior Cortical Atrophy(PCA), Alzheimer's Disease(AD)
Interventions
No intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2070
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

NCT01459302
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Early Phase 1 Interventional

Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study

NCT03707795
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Drug
Lead sponsor
Edward Kasaraskis
Other
Eligibility
20 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational

Amyotrophic Lateral Sclerosis (ALS) Families Project

NCT03865420
View directory record Official record
Conditions
ALS
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 105 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

NCT02781454
View directory record Official record
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Extension Study of Dexpramipexole in ALS

NCT01622088
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Fresno, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05039099
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AP-101, Placebo
Drug
Lead sponsor
AL-S Pharma
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)

NCT01849770
View directory record Official record
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • Iowa City, Iowa • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

NCT01041222
View directory record Official record
Conditions
Familial Amyotrophic Lateral Sclerosis
Interventions
ISIS 333611
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Charlestown, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational

The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study

NCT00317616
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2037
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 17, 2026, 5:14 AM EDT